secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-274261
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta advances NKX019 into second dose cohort; cash runway into 2029
---------------------------------------------------------------------

- Enrollment in second dose-escalation cohort of NKX019 for autoimmune diseases is underway.
- Lymphodepletion with fludarabine+cyclophosphamide shows deep B-cell depletion in all patients vs. partial with cyclophosphamide alone.
- Cash, cash equivalents, and investments of $316.5M as of Sept 30, 2025, expected to fund operations into 2029.
- Net loss of $21.7M ($0.29 per share) for Q3 2025; R&D expenses $20.2M.
- Preliminary data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000119312525274261/0001193125-25-274261-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000119312525274261/nktx-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-274261

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer